Statement of Changes in Beneficial Ownership (4)
2023年5月16日 - 5:37AM
Edgar (US Regulatory)
FORM 4
☐
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
South Cone Investments Limited Partnership |
2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc.
[
RANI
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
AVENIDA PRESIDENTE RIESCO 5711, OFICINA 1603, LAS CONDES |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/11/2023 |
(Street)
SANTIAGO, F3 7550000 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
(City)
(State)
(Zip)
|
Rule 10b5-1(c) Transaction Indication
☐
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to
satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Class A Common Stock | 5/11/2023 | | P | | 2610 | A | $3.8683 (1) | 6863744 | I | Shares indirectly held through South Lake One LLC (3) |
Class A Common Stock | 5/12/2023 | | P | | 2645 | A | $3.9809 (2) | 6866389 | I | Shares indirectly held through South Lake One LLC (3) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.78 to $3.99 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. |
(2) | The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.89 to $4.00 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. |
(3) | South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
South Cone Investments Limited Partnership AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1603, LAS CONDES SANTIAGO, F3 7550000 |
| X |
|
|
South Lake One LLC AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1603, LAS CONDES SANTIAGO, F3 7550000 |
| X |
|
|
Signatures
|
/s/ Isidoro Quiroga Cortes and /s/ Luis Felipe Correa Gonzalez, Managers of South Lake One LLC | | 5/15/2023 |
**Signature of Reporting Person | Date |
/s/ Isidoro Quiroga Cortes and /s/ Luis Felipe Correa Gonzalez,Managers of South Lake Management LLC, as General Partner of South Cone Investments Limited Partnership | | 5/15/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Rani Therapeutics (NASDAQ:RANI)
過去 株価チャート
から 11 2024 まで 12 2024
Rani Therapeutics (NASDAQ:RANI)
過去 株価チャート
から 12 2023 まで 12 2024